# Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT01468532** · PHASE1,PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** pasireotide
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT01468532
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468532, "Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01468532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*